Combinatorial therapy with resveratrol sensitizes glioblastoma to NKG2D CAR-T cells
Preclinical findings identify RSV as a promising pharmacological adjuvant that enhances NKG2D CAR-T efficacy in glioblastoma, supporting further translational and clinical evaluation of this combinatory approach.